Project Grant R41DK145340
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $315K
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- This Project Grant award, valued at $747,133.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research by the Monell Chemical Senses Center to behaviorally, physiologically, anatomically, and molecularly characterize a population of neurons in the nucleus tractus solitarius (NTS) that express glucagon-like peptide-1 receptors (GLP1R) and...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $752,158 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Rerx Therapeutics, Inc. to develop a small molecule therapeutic to address obesity and associated metabolic disorders. The goal is to investigate the efficacy and safety of RERX-001, an orally bioavailable small molecule that targets lipid homeostasis and energy metabolism, in diet-induced...
- This $221,252 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to develop a drug delivery system that modulates adipose (fat) tissue function to enhance metabolism and promote weight management. The key products and services to be delivered under this 12-month grant include: Establishing a correlation between the physicochemical properties of engineered hybrid...
- This federal Project Grant award of $350,000 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The objective is to validate the use of AVGN7 (rAAV6:SMAD7), a gene therapeutic, for treating obesity and type 2 diabetes mellitus (T2DM). The key products or services to be delivered include: (1) Demonstrating that AVGN7 can restore lean body mass and insulin...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- The federal Project Grant award R21HD115119, totaling $531,174, was provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant aims to develop and test novel dual agonist therapies targeting the melanocortin and gut-peptide receptors for the treatment of childhood obesity. The research plan includes two specific aims: 1) fully characterizing and optimizing a GLP-1R/MC4R dual...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $322,800 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Mayo Clinic in Minnesota. This randomized, placebo-controlled trial will examine the effects of long-acting GLP-1 or dual incretin (GLP-1 and GIP) modulation on gastrointestinal functions and their relationship to weight loss. The research aims to investigate the heterogeneous effects of...
- This $802,363 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a research study at Emory University from September 2025 to June 2030 to develop models for predicting the benefits of GLP-1 receptor agonist (GLP-1RA) treatments in preventing obesity-related cardiometabolic diseases. The study aims to use clinical...
- This $361,250 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will support a Phase 2 randomized, placebo-controlled, crossover trial in 20 patients aged 6 years or older with melanocortin obesity syndrome (MCOS) caused by loss-of-function variants in the MC4R gene. The goal is to evaluate the effectiveness of the drug atomoxetine, an...